Form 4: INSMED CFO Sara Bonstein Executes Pre-Planned Stock Option Exercises and Share Sales

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed pre-planned transactions on June 10, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

Summary

• INSMED Inc.'s Chief Financial Officer, Sara Bonstein, engaged in transactions on June 10, 2025, involving both the acquisition and disposition of company shares.
• Ms. Bonstein acquired a total of 47,890 shares of common stock through the exercise of stock options: 24,150 shares at an exercise price of $18.95 per share and 23,740 shares at an exercise price of $17.07 per share.
• Concurrently, she sold a total of 57,776 shares of common stock in multiple transactions at weighted average prices ranging from $87.12 to $91.66 per share.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan that was adopted by Ms. Bonstein on March 5, 2025.
• Following these transactions, Ms. Bonstein's direct beneficial ownership of INSMED common stock stands at 103,412 shares.
• She also continues to hold derivative securities, specifically stock options, for 134,260 shares with a strike price of $18.95 and 35,610 shares with a strike price of $17.07, which vest over time.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these transactions were pre-planned under a 10b5-1 plan mitigates concerns about immediate company performance. The profitable exercise of options also indicates the stock price is significantly above the strike prices, which is generally positive.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to recent company performance or negative news.
• The sales of common stock occurred at significantly higher prices (ranging from $87.12 to $91.66) compared to the exercise prices of the options ($17.07 and $18.95), demonstrating a substantial profit for the insider on these specific transactions.

Negatives

• The sale of a notable number of shares by a key executive (CFO) could be perceived negatively by some investors, even when conducted under a pre-planned trading arrangement.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."
• "The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request."

Industry Context

This document reports an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, even under a 10b5-1 plan, might lead to minor short-term sentiment shifts, but the pre-planned nature typically reduces concerns about company performance or a lack of confidence from the insider.

Next Steps

• Continued vesting of remaining stock options held by the reporting person according to the established schedule.

Key Dates

Recommendation

Keywords

INSMED Inc., INSM, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Chief Financial Officer, Sara Bonstein, Beneficial Ownership